MiSight 1 Day for Myopia Control: A First-Patient Clinical Guide for Optometrists
MiSight® 1 day has made contact-lens-based myopia management considerably easier to integrate into primary optometric practice.
Unlike orthokeratology, there is no corneal reshaping protocol to master. Unlike atropine, there is no concentration to select or medication schedule to manage. And unlike adapting an adult multifocal contact lens for myopia management, MiSight was specifically designed and clinically studied for childhood myopia control.
That simplicity can make MiSight an excellent entry point for an optometrist treating a first myopia-control patient.
The lens is still more than a conventional contact lens, however. The clinician must understand who qualifies under the FDA indication, how the optics work, how to establish an accurate baseline, how to interpret axial-length changes, how frequently to monitor the child, and what to do when progression continues.
This article provides a practical clinical protocol for doing exactly that.
What Is MiSight 1 Day?
MiSight 1 day is an omafilcon A daily disposable soft contact lens manufactured by CooperVision. In the United States, it is FDA approved for both correction of myopia and slowing of myopia progression in appropriately selected children.
The current U.S. product has an 8.7 mm base curve, 14.2 mm diameter, and spherical powers from -0.50 D through -7.00 D, with 0.50 D steps beyond -6.00 D. It is a spherical lens rather than a toric design.
MiSight 1 Day Parameter | Current U.S. Product |
Material | omafilcon A |
Water content | 60% |
Replacement | Daily disposable |
Base curve | 8.7 mm |
Diameter | 14.2 mm |
Available sphere powers | -0.50 D to -7.00 D |
Optical design | Dual-focus concentric treatment design |
Treatment defocus | +2.00 D relative to distance correction |
Toric version | No |
Overnight wear | No |
The FDA device description explains that the optic contains alternating concentric distance-correction and treatment zones. Two zones provide the prescribed distance correction while two treatment zones produce approximately 2.00 D of myopic defocus.
How MiSight Actually Slows Myopia
The central principle is simultaneous myopic defocus.
The distance-correction portions of the lens place the child's refractive correction on the retina so distance vision remains clear. At the same time, the treatment portions of the lens place additional light in front of the retina.
That second optical signal is designed to discourage excessive axial elongation.
This is why MiSight should not simply be thought of as a children's multifocal contact lens. Its alternating optical zones were specifically developed to simultaneously correct the refractive error and provide a myopia-control signal.
The treatment goal is not to make the eye shorter and not necessarily to eliminate all axial growth. Children's eyes normally continue growing.
The clinical goal is to reduce excessive myopic eye growth toward a more physiologic, age-appropriate growth rate.
The FDA Indication Is Important
For a new U.S. MiSight patient, the FDA indication is straightforward.
Treatment should be initiated in children who are:
Requirement | FDA-Labeled Initiation Criteria |
Age | 8–12 years at initiation |
Myopia | -0.75 D to -4.00 D spherical equivalent |
Astigmatism | ≤0.75 D |
Ocular status | Non-diseased eyes |
There is an important distinction between the available lens power range and the FDA-labeled initiation range.
MiSight lenses are currently manufactured through -7.00 D, but the FDA indication still specifies a spherical-equivalent refractive error between -0.75 D and -4.00 D when treatment is initiated. Similarly, the availability of a -0.50 D lens does not change the FDA-labeled lower initiation threshold of -0.75 D.
That distinction becomes particularly important when documenting treatment.
A patient who began appropriately within the indicated age and refractive range may later require stronger lens powers as the child grows. The expanded lens parameters allow many of these children to remain in MiSight without changing modalities.
What About a 13-Year-Old New Patient?
The FDA wording specifies 8 through 12 years of age at initiation of treatment.
Therefore, beginning MiSight in a new 13-year-old patient in the United States falls outside that labeled initiation age.
The same distinction applies to a child beginning treatment with more than -4.00 D spherical equivalent or more than 0.75 D of astigmatism.
That does not answer every clinical question about whether a treatment could be considered, but the clinician should clearly distinguish the FDA-approved indication from any off-label clinical decision.
What About Astigmatism?
MiSight is currently a spherical lens.
The FDA-approved treatment population includes children with 0.75 D or less of astigmatism.
For these patients, the lens can generally be approached using the same principles used to fit a conventional spherical soft contact lens: determine an appropriate spherical contact-lens correction and confirm the result with visual acuity and over-refraction.
If residual cylinder produces unacceptable acuity, ghosting, eyestrain, or poor functional vision, MiSight may not provide an adequate optical correction even though the child technically falls within the labeled astigmatic range.
Do not sacrifice functional vision simply to keep a child in a particular myopia-control modality.
Do You Need Corneal Topography to Fit MiSight?
Usually, no.
MiSight is not orthokeratology. The cornea is not being intentionally reshaped, and the FDA professional labeling states that conventional soft-contact-lens fitting methods apply.
The International Myopia Institute recommends corneal topography when clinically indicated, particularly when contact-lens fitting or corneal shape raises concern, but topography is not inherently required for every uncomplicated MiSight fit.
Topography becomes more valuable when you suspect irregular astigmatism, keratoconus, unusual corneal shape, unexplained reduced BCVA, an abnormal soft-lens fit, or if you are considering orthokeratology as an alternative treatment.
What Should Be Done Before the First MiSight Fit?
A myopia-control consultation should establish considerably more information than simply the child's spectacle prescription.
The International Myopia Institute recommends documenting the child's age, ocular and systemic history, age of myopia onset, previous progression, parental myopia, previous myopia-control treatment, near-work habits, and outdoor exposure. The examination should include refraction, best-corrected acuity, binocular and accommodative assessment when appropriate, anterior-segment evaluation, and axial length when available.
For a first MiSight patient, the most useful baseline is therefore:
Cycloplegic refraction + axial length + ocular health + contact-lens suitability.
A previous spectacle prescription is useful, but it should not substitute for determining the child's current refractive state.
Cycloplegic refraction matters
Children accommodate.
A noncycloplegic refraction can therefore make a child appear more myopic than the actual refractive state, particularly in younger patients.
For myopia management, establishing a dependable refractive baseline is essential because every future measurement will be compared with it. The IMI specifically includes cycloplegic refraction in the myopia-management examination and describes cyclopentolate or tropicamide protocols for obtaining it.
This does not mean that every contact-lens over-refraction must be cycloplegic.
It means you should know the child's true baseline cycloplegic refractive error before judging future progression.
Axial Length Should Be Part of the Conversation
If you have optical biometry available, measure axial length before treatment.
Axial length provides an anatomical measurement of the process we are attempting to control.
Refraction tells you how the optical system has changed.
Axial length tells you how much the eye itself has grown.
The two measurements are related but not interchangeable.
The IMI notes that roughly 0.10 mm per year of axial elongation can be associated with normal childhood eye growth, while approximately 0.20–0.30 mm per year is more commonly associated with progressive myopia. These values are reference points rather than absolute individual treatment-success thresholds because age has a major influence on expected growth.
This becomes particularly useful when explaining treatment to parents.
Instead of saying:
"We're trying to keep the prescription from changing."
The better clinical explanation is:
"We are trying to slow the abnormal elongation of the eye that is driving the increasing prescription."
What Did MiSight Actually Do in the FDA Trial?
The pivotal three-year randomized clinical trial provides an excellent benchmark.
At three years, the FDA analysis found:
Outcome | MiSight | Single-Vision Control |
Cycloplegic myopia progression | -0.65 D | -1.31 D |
Axial elongation | +0.34 mm | +0.62 mm |
The difference was approximately 0.67 D less myopic progression and 0.28 mm less axial elongation with MiSight. Both differences were statistically significant.
Expressed as relative treatment effects, CooperVision reports approximately a 59% reduction in myopia progression and 52% reduction in axial elongation over three years compared with the single-vision daily disposable control lens.
Those percentages are useful when counseling parents, but they should not be presented as a guarantee that an individual child's progression will be reduced by exactly 59%.
Treatment response varies.
The Year-to-Year Axial-Length Data Are Especially Useful Clinically
The pivotal trial provides another useful way to think about treatment response.
Average unadjusted axial elongation was:
Interval | Single-Vision Control | MiSight |
Year 1 | +0.24 mm | +0.09 mm |
Year 2 | +0.21 mm | +0.12 mm |
Year 3 | +0.17 mm | +0.11 mm |
Three-year total | +0.62 mm | +0.30 mm |
This is clinically important.
A successfully treated child does not necessarily demonstrate zero axial elongation.
In the MiSight trial, treated eyes continued to grow. They simply grew substantially less than control eyes.
That is why telling parents that the goal is "no prescription change" can create unrealistic expectations.
A better goal is meaningfully slower progression than would otherwise be expected for that child's age and risk profile.
MiSight Has Longer-Term Data Beyond the Original FDA Trial
The pivotal FDA approval was based primarily on the three-year randomized study, but subsequent peer-reviewed research followed children for longer.
A six-year multicenter study found that the slowing of myopia progression was sustained in children who continued MiSight treatment, and children originally assigned to the single-vision control group also showed slowing after switching to MiSight.
A later cessation analysis found that accumulated treatment gains were retained after stopping prolonged dual-focus treatment, without evidence that the earlier benefit was subsequently lost through accelerated rebound.
These longer-term findings are reassuring, but they should be interpreted separately from the exact wording of the original FDA indication.
How to Choose the First MiSight Lens
MiSight is intentionally simple to fit.
The FDA professional labeling states that conventional contact-lens fitting methods apply, and CooperVision describes the contact-lens evaluation as similar to fitting a spherical daily disposable lens.
Start with an accurate current refraction and determine the appropriate spherical contact-lens power using your normal soft-lens power-selection and vertexing principles.
Once the diagnostic lens is on the eye, evaluate:
distance acuity, binocular acuity, lens centration, complete corneal coverage, movement with blink, comfort, near function, and subjective over-refraction.
The final prescription should provide good functional distance vision without unnecessarily adding minus.
Because the treatment optics deliberately introduce simultaneous defocus, some patients can notice halos, glare, mild ghosting, or reduced contrast, particularly under lower illumination. These symptoms are specifically described in the MiSight safety information.
Ask about them rather than waiting for the child to volunteer the information.
Do Not Chase Every 20/20- Complaint With More Minus
This is an important clinical pearl.
If a child reads slightly better after adding -0.25 D during an over-refraction, that does not automatically mean you should prescribe the additional minus.
Confirm that the improvement is repeatable and functionally meaningful.
Remember that young patients can accommodate through excess minus.
The goal is accurate refractive correction—not creating an artificially crisp endpoint at the expense of over-minus.
Use the child's cycloplegic baseline, manifest response, binocular vision, and actual functional acuity together.
Teach Insertion and Removal Before Sending the Patient Home
For many first-time MiSight patients, insertion and removal will take longer than the actual lens fitting.
Do not treat this as an afterthought.
The child should demonstrate safe insertion and removal before leaving whenever practical, and the parent should understand enough to assist if necessary.
MiSight clinical data and subsequent CooperVision materials show that children as young as eight can successfully handle daily disposable contact lenses.
The parent does not necessarily need to insert the lens every morning.
The child needs a reproducible system.
The Wear Schedule Matters
This is one of the easiest clinical details to overlook.
Based on the clinical study, CooperVision recommends at least 10 hours of wear per day for at least six days per week.
Therefore, "I wear them sometimes for soccer" is not equivalent to the treatment protocol used to establish efficacy.
When evaluating apparent treatment failure, ask specifically:
How many days per week are you wearing them?
What time do you put them in?
What time do you take them out?
Do you wear them on weekends?
A child wearing MiSight four hours per day after school is not receiving the same treatment exposure as a child wearing the lenses throughout the school day and evening.
Daily Disposable Means Daily Disposable
MiSight lenses should be discarded whenever they are removed.
They are not designed to be cleaned, stored, and reused the next day. They are also not approved for overnight wear.
Every MiSight child should also retain an appropriate pair of backup spectacles.
The FDA labeling specifically recommends access to replacement lenses or spectacles.
Water Exposure Should Be Explicitly Discussed
Children swim.
Children shower in their contacts.
Children forget.
Do not assume the family understands that water exposure is a contact-lens safety issue.
CooperVision's safety information instructs patients not to expose MiSight lenses to water while wearing them. If lenses are worn during swimming, the guidance is to discard them afterward and replace them with a fresh pair.
No sleeping.
No showering in lenses.
No saliva.
No reusing yesterday's lens.
Those four instructions prevent a large proportion of avoidable contact-lens problems.
When Should the First Follow-Up Be?
For soft-contact-lens-based myopia management, the World Council of Optometry describes a practical review schedule of:
1 week → 1 month → 6 months → 1 year, followed by continued surveillance.
At the early visits, you are primarily evaluating the contact lens.
At six months and beyond, you are increasingly evaluating the myopia-control treatment.
At every contact-lens follow-up, document visual acuity, lens fit, comfort, adherence, over-refraction, and anterior-segment health.
At approximately six months, repeat axial length and ideally cycloplegic refraction.
At the annual visit, perform the child's complete comprehensive ocular-health examination as well.
A Practical MiSight Follow-Up Protocol
Visit | Main Purpose |
Initial evaluation | Establish cycloplegic refraction, axial length, ocular health and candidacy |
Dispense | Confirm fit, acuity, comfort and insertion/removal |
1 week | Check handling, comfort, wear time, VA and anterior segment |
1 month | Confirm stable fit, adherence and functional vision |
6 months | Repeat progression assessment, including axial length and preferably cycloplegic refraction |
12 months | Repeat full myopia-control evaluation and comprehensive ocular-health examination |
Thereafter | Usually every 6 months for progression monitoring |
This schedule can be modified for the individual patient.
A nervous first-time wearer, questionable fit, ocular-surface issue, poor compliance, unexpectedly reduced acuity, or unusually rapid progression warrants earlier review.
How Do You Know Whether MiSight Is Working?
Do not judge treatment from a single prescription change.
Compare the child's trajectory.
The two most important longitudinal measurements are:
cycloplegic spherical-equivalent refraction and axial length.
The IMI notes that traditional single-vision correction is commonly associated with approximately 0.50–1.00 D of annual childhood myopia progression, while axial elongation around 0.20–0.30 mm per year is commonly associated with increasing myopia. Age must always be considered because younger children normally progress faster.
If an eight-year-old grows 0.08 mm over six months, that does not automatically mean failure.
If a child grows 0.12 mm over six months, that also does not automatically mean the lens is ineffective.
The first question is:
How does that growth compare with the child's age, previous trajectory, adherence, refraction, and expected untreated progression?
Myopia management is longitudinal medicine.
Trends matter more than isolated numbers.
What Should You Do When Progression Looks Too Fast?
Before abandoning MiSight, verify the fundamentals.
Was the baseline refraction cycloplegic and reliable?
Was axial length measured on the same instrument?
Is the child actually wearing the lenses at least approximately 10 hours per day and six days per week?
Has the refractive correction become underpowered?
Is residual astigmatism degrading vision?
Has near behavior changed substantially?
Is the child younger and therefore naturally progressing more rapidly?
Is the axial-length change repeatable?
The World Council of Optometry specifically recommends reassessing baseline refraction, axial-length expectations, adherence, and whether the chosen modality fits the child's lifestyle when progression appears greater than expected.
Only after answering those questions should you label the response inadequate.
When Should You Change Treatment?
There is no universally accepted axial-length number that automatically defines MiSight failure.
A patient who continues elongating at a rate resembling untreated progressive myopia despite good adherence deserves reassessment, but the decision should be based on the overall trajectory rather than one measurement.
If clinically meaningful progression persists despite good wear, accurate correction, good lens fit, and appropriate monitoring, the IMI notes that treatment may be switched or augmented with another myopia-management modality.
That decision moves beyond a simple MiSight fitting and into individualized myopia management.
When Should MiSight Be Stopped?
Do not automatically discontinue treatment because the child turns 13, 14, or 15.
The FDA indication refers to age at initiation, not an instruction to stop treatment on the child's thirteenth birthday.
Myopic progression frequently continues through adolescence.
The more useful question is whether axial length and refractive error have stabilized over time.
The World Council of Optometry recommends continued six-month monitoring even after apparent stabilization and notes that optical myopia-control treatments are commonly continued through childhood.
Treatment cessation should therefore be based on the child's progression pattern rather than an arbitrary birthday.
Safety: What the Parent Needs to Understand
MiSight has the safety considerations of daily-wear soft contact lenses.
Potential complications include inflammatory events, corneal abrasions, infection, and microbial keratitis.
The original FDA labeling included a retrospective analysis of 782 children wearing conventional daily-wear soft contact lenses, representing 2,134 patient-years. Two cases of microbial keratitis were identified, corresponding to an estimated rate of 9.4 cases per 10,000 patient-years, although the confidence interval was wide and these were not MiSight wearers.
The clinical message is not that contact lenses are unsafe for children.
It is that contact-lens hygiene remains medically important even when the lens is being prescribed as myopia treatment.
Pain, significant redness, photophobia, discharge, or an unexplained reduction in vision should trigger immediate lens removal and prompt evaluation.
One of the Biggest Mistakes: Talking Only About the Prescription
Parents understand diopters because they see the spectacle prescription.
But myopia management is fundamentally about the eye itself.
Whenever possible, show the parent the axial-length measurement.
For example:
Baseline: 24.36 mm
Six months: 24.40 mm
Change: +0.04 mm
That conversation is much more powerful than saying:
"Her prescription didn't change much."
It also makes future treatment decisions easier because the parent understands what you are measuring and why.
Another Mistake: Promising 59% Control
The pivotal trial demonstrated an average relative reduction of approximately 59% in myopic refractive progression compared with the control lens.
That is population-level efficacy.
It does not mean:
"Your child's myopia will progress exactly 59% less."
The better conversation is:
"Clinical studies show that children wearing MiSight progressed substantially less on average than children wearing conventional single-vision contacts. Your child's response may be greater or smaller, which is why we monitor both prescription and eye growth."
That sets the correct expectation from day one.
You Do Not Have to Be an Ortho-K Expert to Start Myopia Management
This may be MiSight's biggest practical advantage for general optometry.
The lens uses a familiar daily disposable soft-contact-lens workflow.
There is one base curve.
One diameter.
No overnight lens wear.
No topographic treatment zone to center.
No toric stabilization system.
No atropine concentration decision.
No cleaning system.
CooperVision has also stated that its previous U.S. MiSight certification requirement was eliminated, while the company continues to provide QuickStart educational resources for practitioners.
The clinician still needs to understand myopia biology and progression.
But the actual contact-lens fitting is intentionally straightforward.
Your First MiSight Patient: Chairside Checklist
Confirm the child is within the FDA-labeled initiation criteria: age 8–12, -0.75 D to -4.00 D spherical equivalent, ≤0.75 D astigmatism, non-diseased eyes.
Review previous prescriptions to estimate the child's historical progression.
Ask about age of onset, parental myopia, outdoor exposure and near-work habits.
Obtain an accurate baseline refraction, preferably including cycloplegia.
Measure baseline axial length with optical biometry if available.
Document BCVA, binocular status as indicated, anterior-segment health and dilated posterior-segment findings.
Select the initial MiSight power using normal spherical soft-contact-lens fitting principles.
Confirm distance and near vision, centration, coverage, movement, comfort and over-refraction.
Ask specifically about halos, glare, ghosting and contrast.
Complete insertion and removal training.
Prescribe approximately 10+ hours/day, at least 6 days/week.
Reinforce no sleeping, no water exposure and no lens reuse.
Make sure the child has backup spectacles.
Schedule approximately 1-week and 1-month contact-lens checks.
Repeat axial length and progression assessment at approximately 6 months.
Repeat comprehensive examination and treatment review annually.
Continue six-month progression monitoring even when treatment appears successful.
The Bottom Line
For an optometrist seeing a first myopia-control patient, MiSight 1 day is one of the most straightforward ways to begin active myopia management.
The contact-lens fitting itself is relatively simple.
The more important skill is learning how to manage the disease longitudinally.
Start with a reliable cycloplegic refractive baseline.
Measure axial length whenever possible.
Fit the lens like a well-centered spherical daily disposable.
Encourage sufficient daily wear.
Monitor ocular health.
Recheck progression approximately every six months.
And judge success based on the child's trajectory of axial elongation and refractive progression—not whether the prescription changes by exactly zero.
Once those principles are understood, a MiSight patient stops feeling like a specialty contact-lens case.
It becomes what myopia management should increasingly become in primary optometric practice: routine care for a progressive childhood refractive condition.
Comments